Oxford BioMedica accelerates viral vector development and manufacture

(Alliance News) - Oxford Biomedica PLC on Monday announced the launch of fast-track offering for adeno-associated viral vectors and lentiviral vector platforms.

The Oxford, England-based gene and cell therapy developer said the launch speeds up viral vector development and manufacture.

Oxford Biomedica said: "For the manufacture of lentiviral vectors, OXB's fast-track offering accelerates an industry-standard 12-18 month timeline to as little as nine months, through the use of platform datasets and advanced analytics, and proceeding directly from scale-down models into GMP manufacturing. Additional efficiencies are achieved through the integration of vector design, production, purification, and fill-finish, shortening timelines."

Chief Business Officer Sebastien Ribault said: "For emerging cell and gene therapy companies, viral vector development and manufacture represents a frequent bottleneck to clinical readiness, and issues can delay critical clinical milestones. The launch of our fast-track offering will make our proprietary inAAVate and LentiVector platforms accessible to a wider range of clients who are looking for an expedited route to good manufacturing practice [GMP] manufacture and the clinic, cutting industry standard development timelines by up to 50%."

Oxford Biomedica shares were 0.4% lower at 564.00 pence each on Monday morning in London.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Oxford Biomedica